Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts within the central nervous system to relieve persistent pain. It is prescribed for: - Chronic musculoskeletal pain: provides long‑lasting relief for conditions such as osteoarthritis and low‑back pain. - Neuropathic pain associated with diabetic neuropathy: helps reduce pain intensity in peripheral nerve damage. - Cancer‑related chronic pain: contributes to multimodal pain control in oncology patients.

Adverse reactions to Palexia Retard can vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach feeling. - Constipation: reduced bowel movements, often requiring dietary management. - Dizziness: transient light‑headedness, especially when standing quickly. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may require medical attention. - Seizures: rare occurrence of convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of developing opioid use disorder. - Withdrawal syndrome: symptoms upon abrupt discontinuation.

When prescribing Palexia Retard, clinicians should consider several safety aspects. - Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy. - Monitor for respiratory depression: especially during dose titration and in patients with pulmonary disease. - Evaluate renal and hepatic function: dose adjustments may be needed in impairment. - Avoid concomitant CNS depressants: reduces risk of additive sedation and respiratory effects. - Educate patients on proper use and disposal: prevent accidental ingestion and diversion. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Palexia Retard may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - MAO inhibitors: increase risk of hypertensive crisis or serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., quinidine): raise tapentadol plasma levels, heightening adverse effects.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., SSRIs, SNRIs): may augment risk of serotonin syndrome. - Antihistamines with sedative properties: can enhance drowsiness. - Diuretics: may intensify orthostatic hypotension. - Alcohol: additive central nervous system depression.